IgG Next Generation is a newly developed polyvalent immunoglobulin preparation for intravenous administration from human plasma for the treatment of immunodeficiencies and autoimmune diseases.
IgG Next Generation will be submitted for approval in several European countries and USA. Clinical development has been successfully completed in two pivotal trials: phase III Study No. 991 for the treatment of patients with primary immunodeficiencies (PID) and phase III Study No. 992 for the treatment of patients with immune thrombocytopenia (ITP). Study No. 991 has been closed and is currently being evaluated, while Final results are already available for Study No. 992, confirming the expectations regarding efficacy and safety of the drug.